Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Asset Utilization Ratio (2016 - 2024)

Spyre Therapeutics (SYRE) has disclosed Asset Utilization Ratio for 8 consecutive years, with 0.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Asset Utilization Ratio fell 91.2% year-over-year to 0.0, compared with a TTM value of 0.0 through Mar 2024, down 91.2%, and an annual FY2023 reading of 0.0, down 83.32% over the prior year.
  • Asset Utilization Ratio was 0.0 for Q1 2024 at Spyre Therapeutics, down from 0.0 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 0.3 in Q1 2022 and bottomed at 0.0 in Q1 2024.
  • Average Asset Utilization Ratio over 4 years is 0.09, with a median of 0.04 recorded in 2022.
  • The sharpest move saw Asset Utilization Ratio surged 140.34% in 2022, then plummeted 95.53% in 2023.
  • Year by year, Asset Utilization Ratio stood at 0.23 in 2021, then crashed by 87.63% to 0.03 in 2022, then crashed by 88.73% to 0.0 in 2023, then plummeted by 48.59% to 0.0 in 2024.
  • Business Quant data shows Asset Utilization Ratio for SYRE at 0.0 in Q1 2024, 0.0 in Q4 2023, and 0.0 in Q3 2023.